AKBA

Nov 05, 11:11 AMAkebia Q3 2026 posts $0.04 loss per share on $36.9M revenue, missing estimates

Peers: ARDX UNCY RMTI AMGN GSK OPK PROK TVTX VERA DVA

| Held by: VTI IWM VXF IWO FESM VTWO SCHA VHT IWC SMLF

Index	RUT
Market Cap	121.87M
Enterprise Value	175.42M
Income	-29.67M
Sales	219.06M
Book/sh	0.09
Cash/sh	0.57
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	194
IPO	Mar 20, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	0.56
P/B	4.78
P/C	0.77
P/FCF	3.03
EV/EBITDA	-
EV/Sales	0.80
Quick Ratio	1.35
Current Ratio	1.43
Debt/Eq	8.43
LT Debt/Eq	6.44
Option/Short	Yes / Yes

EPS (ttm)	-0.11
EPS next Y	-0.31
EPS next Q	-0.04
EPS this Y	-600.00%
EPS next Y	-122.62%
EPS next 5Y	-
EPS past 3/5Y	65.70% 62.40%
Sales past 3/5Y	-6.88% -4.37%
EPS Y/Y TTM	35.69%
Sales Y/Y TTM	7.52%
EPS Q/Q	-3766.67%
Sales Q/Q	-21.36%
Earnings	Nov 05 BMO
EPS/Sales Surpr.	-38.89% -21.38%

Insider Own	2.71%
Insider Trans	-0.74%
Inst Own	39.76%
Inst Trans	3.21%
ROA	-8.53%
ROE	-109.38%
ROIC	-15.93%
Gross Margin	78.92%
Oper. Margin	-6.02%
Profit Margin	-13.54%
SMA20	-33.12%
SMA50	-45.96%
SMA200	-61.00%
Trades

Shs Outstand	271.74M
Shs Float	269.58M
Short Float	8.56%
Short Ratio	2.82
Short Interest	23.07M
52W High	2.11 -79.16%
52W Low	0.42 3.78%
Volatility	12.14% 9.85%
ATR (14)	0.07
RSI (14)	27.97
Beta	0.36
Rel Volume	0.01
Avg Volume	8.19M
Volume	2,597

Perf Week	-37.75%
Perf Month	-46.02%
Perf Quarter	-47.89%
Perf Half Y	-62.09%
Perf YTD	-72.68%
Perf Year	-78.12%
Perf 3Y	-56.02%
Perf 5Y	-84.99%
Perf 10Y	-94.03%
Recom	1.33
Target Price	3.75
Prev Close	0.43
Price	0.44
Change %	3.36%

Consensus

Strong Buy

Avg. Price Target

$3.75

Implied Upside

+752.7%

Analysts11incl. previous ratings

Rating Distribution5 Buy · 5 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 07, 2026	Downgrade	LLeerink Partners	Outperform → Market Perform	$1	+127.4%
Jun 04, 2025	Resumed	HH.C. Wainwright	Buy	$8	+1,719.0%
Apr 28, 2025	Initiated	LLeerink Partners	Outperform	$7	+1,491.6%
Apr 01, 2025	Initiated	JJefferies	Buy	$6	+1,264.3%
Nov 29, 2023	Resumed	BBTIG Research	Buy	$4	+809.5%
Aug 28, 2023	Upgrade	HH.C. Wainwright	Neutral → Buy	$3.75	+752.7%
May 31, 2023	Upgrade	PPiper Sandler	Neutral → Overweight	$2 → $4	+809.5%
Mar 31, 2022	Downgrade	PPiper Sandler	Overweight → Neutral	$8 → $2	+354.8%
Mar 31, 2022	Downgrade	NNeedham	Buy → Hold
Mar 31, 2022	Downgrade	MMizuho	Buy → Neutral	$6 → $2	+354.8%
Mar 31, 2022	Downgrade	HH.C. Wainwright	Buy → Neutral	$10 → $2	+354.8%
Mar 08, 2021	Initiated	CCantor Fitzgerald	Overweight	$8	+1,719.0%
Jan 29, 2021	Downgrade	JJP Morgan	Neutral → Underweight
Nov 14, 2019	Reiterated	NNeedham	Buy	$18 → $15	+3,310.6%
Aug 06, 2019	Reiterated	HH.C. Wainwright	Buy	$19 → $17	+3,765.4%
Jul 11, 2019	Reiterated	HH.C. Wainwright	Buy	$23 → $21	+4,674.9%
May 02, 2019	Initiated	JJP Morgan	Overweight	$12	+2,628.5%
Mar 20, 2019	Initiated	CCitigroup	Neutral	$9	+1,946.4%
Sep 07, 2018	Resumed	MMorgan Stanley	Equal-Weight
Aug 10, 2018	Reiterated	NNeedham	Buy	$20 → $18	+3,992.8%

Nov-05-26 10:46AM	Akebia Misses As Vafseo Destocking And A Sharply Lower Post-TDAPA Price Overshadow Its Best Clinical Evidence Yet (Earnings Whispers) -38.75%
07:24AM	Akebia Therapeutics: Q3 Earnings Snapshot (Associated Press)
07:10AM	Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
07:00AM	Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin (GlobeNewswire)
Oct-29-26 11:51AM	Akebia's Vafseo Ramp Faces Its First Post-VOICE Test As Auryxia Erosion Drags The Top Line (Earnings Whispers)
08:00AM	Loading…
08:00AM	Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Oct-26-26 09:20AM	U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week (GlobeNewswire) +13.57%
Oct-07-26 08:00AM	Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum (GlobeNewswire)
Oct-06-26 08:00AM	Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia's Rare Kidney Pipeline at ASN Kidney Week 2026 (GlobeNewswire)
Oct-01-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.33%
Sep-14-26 08:00AM	Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases (GlobeNewswire)
Sep-01-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston (GlobeNewswire)
Aug-06-26 01:10AM	Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ... (GuruFocus.com) -26.02%
Aug-05-26 05:04PM	Akebia Therapeutics: Q2 Earnings Snapshot (Associated Press)
04:05PM	Loading…
04:05PM	Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
Aug-03-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases (GlobeNewswire)
Jul-29-26 08:00AM	Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Jul-02-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-30-26 08:00AM	U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA (GlobeNewswire)
Jun-10-26 08:00AM	Akebia Therapeutics Strengthens Vafseo (vadadustat) Patent Portfolio (GlobeNewswire) -5.12%
Jun-01-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.20%
May-28-26 08:00AM	Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-07-26 07:10AM	Akebia Therapeutics: Q1 Earnings Snapshot (Associated Press) -20.27%
07:00AM	Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights (GlobeNewswire)
May-04-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.14%
08:00AM	Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology (GlobeNewswire)
Apr-30-26 04:05PM	Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Apr-13-26 08:00AM	Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 (GlobeNewswire) +5.00%
08:00AM	Loading…
Apr-07-26 08:00AM	Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium (GlobeNewswire)
Apr-02-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-26 04:05PM	Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors (GlobeNewswire)
Mar-19-26 04:05PM	Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 (GlobeNewswire)
Mar-03-26 08:00AM	Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire)
Mar-02-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-26 04:14PM	Akebia Therapeutics Inc (AKBA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com) +9.09%
09:16AM	Akebia Therapeutics Q4 Earnings Call Highlights (MarketBeat)
07:30AM	Akebia Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights (GlobeNewswire)
Feb-19-26 07:28PM	Piper Sandler Lowers Akebia Therapeutics (AKBA) PT to $4 as Firm Updates Estimates Following Year-End Reports (Insider Monkey)
05:10PM	Ardelyx (ARDX) Reports Break-Even Earnings for Q4 (Zacks)
08:00AM	Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Feb-12-26 10:34AM	Akebia Therapeutics Spotlights VAFSEO Dialysis Push, TIW Dosing Plan and Rare Kidney Pipeline at Summit (MarketBeat) -12.26%
Feb-04-26 08:00AM	Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Feb-02-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-12-26 08:00AM	Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook (GlobeNewswire) -7.89%
Jan-07-26 08:22AM	Akebia announces first patient dosed in Phase 2 trial of praliciguat (TipRanks)
Jan-06-26 08:00AM	Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) (GlobeNewswire)
Jan-05-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-28-25 12:46PM	Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat (Insider Monkey)
Dec-02-25 11:28AM	This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here? (Barchart)
Dec-01-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Q32 Bio Sells Complement Inhibitor ADX-097 (PR Newswire)
07:00AM	Akebia Announces Establishment of Rare Kidney Disease Pipeline (GlobeNewswire)
Nov-24-25 08:00AM	Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 11:01AM	Implied Volatility Surging for Akebia Therapeutics Stock Options (Zacks)
Nov-11-25 10:10AM	Theravance's Q3 Earnings Surpass Estimates, Revenues Match (Zacks) +8.38%
09:35AM	Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-10-25 02:01PM	Akebia Therapeutics Inc (AKBA) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com) -18.14%
07:00AM	Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-07-25 12:51PM	Mettler-Toledo Q3 Earnings Top Estimates, Sales Decline Y/Y (Zacks)
Nov-06-25 06:55PM	Globus Medical (GMED) Tops Q3 Earnings and Revenue Estimates (Zacks) -5.19%
06:30PM	Vafseo (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs (GlobeNewswire)
Nov-05-25 05:50PM	Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-04-25 08:00AM	Akebia Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-03-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-30-25 08:00AM	Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Oct-28-25 04:30PM	Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients (GlobeNewswire) -32.04%
Oct-20-25 08:08AM	Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025 (GlobeNewswire) +7.85%
Oct-15-25 06:19AM	Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics (Zacks) +5.73%
Oct-14-25 10:57AM	5 Small Drug Stocks to Buy as the Industry Shows Some Recovery (Zacks)
Oct-08-25 09:40AM	Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-01-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-24-25 03:48AM	Karyopharm Therapeutics (KPTI) Moves 27.9% Higher: Will This Strength Last? (Zacks)
Sep-02-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-28-25 08:00AM	Akebia Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-21-25 08:00AM	Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo (vadadustat) Across All IRC Dialysis Clinics (GlobeNewswire)
Aug-20-25 12:22AM	Akebia Therapeutics (AKBA) Bounces to Profitability amid Kidney Treatment Growth (Insider Monkey)
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -20.48%
08:25AM	Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2 (Zacks)
07:00AM	Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-06-25 06:15PM	OmniAb, Inc. (OABI) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference (GlobeNewswire)
Aug-04-25 08:00AM	Akebia Initiates Vafseo (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization (GlobeNewswire)
Aug-01-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:40AM	Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year? (Zacks)
Jul-31-25 08:00AM	Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Jul-25-25 12:09PM	H.C. Wainwright Rates Akebia Therapeutics (AKBA) Stock Buy (Insider Monkey) -7.29%
Jul-22-25 11:03AM	Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share (Insider Monkey)
Jul-16-25 12:00PM	Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
09:40AM	Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-08-25 08:00AM	Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference (GlobeNewswire)
Jul-07-25 09:10AM	Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT (Insider Monkey)
Jul-02-25 10:08PM	Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase (Insider Monkey)
Jul-01-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:42AM	Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials (Insider Monkey)
Jun-17-25 09:53AM	Averoa secures EC authorisation for oral CKD treatment (Pharmaceutical Technology)
Jun-04-25 08:00AM	Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology (GlobeNewswire) +6.43%
Jun-02-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.26% +5.23%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Butler John P.	CEO and President	Aug 06 '26	Option Exercise	0.63	350,000	220,500	3,718,564	Aug 10 04:08 PM
Ostrowski Erik	SVP, CFO, CBO & Treasurer	Jun 29 '26	Sale	1.11	56,019	62,181	616,616	Jul 01 04:34 PM
Ostrowski Erik	Officer	Jun 29 '26	Proposed Sale	1.11	56,019	62,220		Jun 29 08:38 PM
Butler John P.	CEO and President	Mar 04 '26	Buy	1.25	69,270	86,588	3,367,064	Mar 05 06:55 PM
Malabre Richard C	SVP, Chief Accounting Officer	Feb 02 '26	Sale	1.39	49,524	68,838	299,390	Feb 04 04:15 PM
Grund Nicholas	Chief Commercial Officer	Feb 02 '26	Sale	1.39	84,829	117,912	561,750	Feb 04 04:13 PM
Burke Steven Keith	SVP, Chief Medical Officer	Feb 02 '26	Sale	1.39	67,658	94,045	948,432	Feb 04 04:13 PM
Rucci Carolyn M.	SVP, Chief Legal Officer	Feb 02 '26	Sale	1.39	69,772	96,983	588,378	Feb 04 04:12 PM
Ostrowski Erik	SVP, CFO, CBO & Treasurer	Feb 02 '26	Sale	1.39	34,951	48,582	672,635	Feb 04 04:11 PM
Butler John P.	CEO and President	Feb 02 '26	Sale	1.39	341,305	474,414	3,206,233	Feb 04 04:10 PM
Ostrowski Erik	Officer	Feb 02 '26	Proposed Sale	1.39	34,951	48,739		Feb 02 05:58 PM
Grund Nicholas	Officer	Feb 02 '26	Proposed Sale	1.39	84,829	118,294		Feb 02 05:57 PM
Burke Steven Keith	Officer	Feb 02 '26	Proposed Sale	1.39	67,658	94,349		Feb 02 05:55 PM
Butler John P.	Officer	Feb 02 '26	Proposed Sale	1.39	341,305	475,950		Feb 02 05:54 PM
Rucci Carolyn M.	Officer	Feb 02 '26	Proposed Sale	1.39	69,772	97,297		Feb 02 05:52 PM

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice Jr., Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

CEOMr. John P. Butler MBA

Chief Business OfficerMr. Erik John Ostrowski M.B.A.

Senior VP and Chief Research & Development OfficerDr. Steven Keith Burke M.D.

Senior VP & Chief Commercial OfficerMr. Nicholas Grund

Senior VP & Chief Accounting OfficerMr. Richard C. Malabre

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Akebia Therapeutics Inc

Upgrade your Finviz experience